This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Milatuzumab

Immunomedics, Inc.

Drug Names(s): I MMU-115, hLL1

Description: Please also see doxorubicin-conjugated milatuzumab.

Milatuzumab is a naked humanized monoclonal antibody (ie without any attached drugs or radioactive material) targeting the CD74 antigen. CD74 is a chaperone molecule (a rapidly internalizing type-II transmembrane chaperone) associated with MHC class II, directing transport from the cell surface to an endosomal compartment. CD74 has also been implicated as an accessory-signaling molecule. High expression of CD74 has been observed in human non-Hodgkin’s lymphoma and multiple myeloma clinical specimens and cell lines.


Milatuzumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug